Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US blood companies to use NAT (nucleic acid testing) for HIV/HCV, says FDA:

This article was originally published in Clinica

Executive Summary

The US FDA has gently warned blood manufacturers that they need to begin incorporating nucleic acid testing technology (NAT) to screen for HIV-1 and Hepatitis C. In a draft guidance document issued last week, the agency said that manufacturers should implement NAT testing for the two viruses within six months of final guidance being issued. The notice was published in the Federal Register on April 9. Comments are due by July 8 so the agency can prepare the final document, the FDA said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel